Alnylam Pharmaceuticals (ALNY) FCF Margin (2009 - 2026)
Alnylam Pharmaceuticals' (ALNY) quarterly FCF Margin came in at 22.62% in Q2 2026, up 769.0% YoY from 2.6% in Q2 2025, and up 442.51% on a QoQ basis from 4.17% in Q1 2026.
Alnylam Pharmaceuticals (ALNY) FCF Margin (2009 - 2026) Analysis & Trends
Alnylam Pharmaceuticals (ALNY) has 18 years of FCF Margin data on file, last reported at 22.62% in Q2 2026.
- Quarterly FCF Margin rose 769.0% year-over-year to 22.62% in Q2 2026, while the trailing twelve-month figure through Jun 2026 was 17.07% (up 2118.0% YoY) and the FY2025 annual result came in at 12.53%, up 1443.0% from the prior year.
- FCF Margin advanced to 22.62% in Q2 2026, from 4.17% in the prior quarter.
- In the past five years, FCF Margin ranged from a high of 45.61% in Q3 2023 to a low of 430.94% in Q1 2025.
- A 5-year average of 36.18% and a median of 13.87% in 2024 frame the typical range for FCF Margin.
- Annual changes were most pronounced in 2025 — FCF Margin sank 41183 bps — and 2026, when it surged 43511 bps.
- Tracing ALNY's FCF Margin over 5 years: stood at 45.85% in 2022, then soared by 78 bps to 10.26% in 2023, then sank by 71 bps to 17.49% in 2024, then jumped by 173 bps to 12.79% in 2025, then soared by 77 bps to 22.62% in 2026.
- The last three FCF Margin figures came in at 22.62% (Q2 2026), 4.17% (Q1 2026), and 12.79% (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 30.39% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 13.35% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 25.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -77,594.17% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 70.82% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 22.62% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -22.35% |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | -18,629.40% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 22.62% |
| Mar 31, 2026 | 4.17% |
| Dec 31, 2025 | 10.43% |
| Sep 30, 2025 | 27.12% |
| Jun 30, 2025 | 18.28% |
| Mar 31, 2025 | -21.76% |
| Dec 31, 2024 | -17.49% |
| Sep 30, 2024 | 3.91% |
| Jun 30, 2024 | 19.00% |
| Mar 31, 2024 | -16.94% |
| Dec 31, 2023 | 3.03% |
| Sep 30, 2023 | 45.61% |
| Jun 30, 2023 | -23.50% |
| Mar 31, 2023 | -56.49% |
| Dec 31, 2022 | -59.06% |
| Sep 30, 2022 | -33.12% |
| Jun 30, 2022 | -61.77% |
| Mar 31, 2022 | -88.65% |
| Dec 31, 2021 | -42.26% |
| Sep 30, 2021 | -85.33% |